German Merck obtains exclusive global development rights for xevinapant

Source: Immediate Medicine News

On March 1, 2021, Debiopharm announced that it has signed an exclusive license agreement for the development and commercialization of xevinapant (Debio1143) with German Merck (Merck KGaA).

According to the terms of the license agreement, Merck, Germany, has obtained the exclusive global development and commercialization rights of xevinapant, and will co-fund the ongoing Phase 3 registered TrilynX study with Debiopharm, which aims to evaluate the deterministic standard of chemoradiation therapy (chemoradiation therapy, CRT) based on the efficacy and safety of xevinapant and placebo.

The results of a previously reported randomized, double-blind phase 2 clinical study showed that the addition of xevinapant to the standard treatment of CRT improved the local area control rate by 21% at 18 months, which was statistically significant and reached the primary endpoint.

Squamous cell carcinoma of the head and neck is the sixth most common type of cancer in the world, and more than half of the patients have locally advanced tumors at the time of diagnosis.

Mr.

Mr.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

Reference materials:

[1] Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant.